SSG
CVAC

Summit Securities Group’s CureVac CVAC Stock Holding History

Summit Securities Group’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-194
Closed -$537 – 1146
2025
Q1 		$537 Buy
+194
New +$675 ﹤0.01% 720
2024
Q4 		– Sell
-158
Closed – – 690
2024
Q3 		$0 Buy
+158
New +$521 ﹤0.01% 638

Other funds holding CVAC

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Summit Securities Group's CVAC Position: Q2 2025 in Review

Summit Securities Group sold out of CureVac (CVAC) in Q2 2025, closing a stake of 194 shares — an estimated $537 sold.

Summit Securities Group first reported a position in CVAC in Q3 2024 and held it in 2 quarters. The position peaked at $537 in Q1 2025. 91 funds tracked by Wall St. Rank hold CVAC as of Q2 2025.

  • Summit Securities Group reported no remaining CureVac position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 194 CureVac shares in Q2 2025, an estimated $537.
  • Summit Securities Group first reported a position in CureVac in Q3 2024 and held it in 2 quarters.
  • Summit Securities Group's CureVac position peaked at $537 in Q1 2025.
  • 91 funds tracked by Wall St. Rank held CureVac as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.